Did You Know...

The Duke Health Plans including Duke Basic, Duke Select, and Duke BCBS plans (Blue Care and Duke Options) utilize the Express Scripts National Preferred Formulary to determine medication coverage for patients in the outpatient setting. This formulary does not apply to those who are ≥65 years of age and covered by the Duke retiree plan. Beginning January 1, 2020 several changes will go into effect regarding drug coverage.

The medications below (including 8 specialty products *) will be excluded from the formulary and thus will no longer be covered. Each has covered alternatives within their respective drug class.

Each of the multi-source branded products has a generic formulation available. For example, BRAND Lyrica will not be covered but the generic (pregabalin) will be covered.

Several medications will be ADDED to formulary coverage including select Freestyle diabetes testing supplies (Freestyle Lite and Freestyle Freedom Lite will be co-preferred with OneTouch products in 2020).

NEW FORMULARY EXCLUSIONS		
AKYNZEO CAPSULE	NUWIQ*	SITAVIG
AUBAGIO*	ONZETRA XSAIL	STRIVERDI RESPIMAT
EMEND POWDER PACKET	ORFADIN*	SUBSYS
EPANED	PENNSAID	TIVORBEX
GRANIX*	QBRELIS	VIVLODEX
JADENU*, JADENU SPRINKLE*	RELION NOVOLIN	XATMEP
MULPLETA*	RHOFADE	ZIPSOR
MULTI-SOURCE BRAND EXCLUSIONS (generic WILL be covered)		
AMBIEN, AMBIEN CR	ELIDEL	LYRICA
AMRIX	EMEND CAPSULE, TRIFOLD PACK	RAPAFLO
CIALIS	EXJADE*	
CUPRIMINE	FOCALIN, FOCALIN XR	

^{*}specialty medication

For a full list of all the excluded medications, please refer to the handout attached. These formulary changes will affect <0.1% of those covered by the Duke plan. Additionally, flyers with instructions on how patients can obtain a new diabetes meter are attached as well.

For any patient who is unable to use one of the alternative medications due to a clinical reason, a clinical exception process is in place. A provider or their staff may call 1-800-753-2851, provide the clinical rationale, and request coverage. The rationale will be reviewed by Express Scripts and a coverage determination will be made accordingly.

This communication was approved by the PDC Ambulatory Pharmacy Workgroup. For more information, please contact Lee Jackson at lee.jackson@dm.duke.edu.